WHY ARE WE DOING THIS RESEARCH?*
COVID-19 can cause great suffering, and it stops people from performing their daily activities, affecting their work, education, and caring responsibilities. The risk of complications from COVID-19 is increased in people with underlying health conditions, older people, unvaccinated people, and those in whom the vaccine is less effective. Especially in these people, COVID-19 can sometimes lead to significant medical problems, hospitalisation, and death.
The purpose of this clinical study is to find new treatments that help those suffering with COVID-19 at home and in the community get better quicker and without needing to be treated in hospital. Most people with COVID-19 are treated in the community and so we need to find treatments that are suitable and effective for use early on in the illness.
PANORAMIC aims to find out if new antiviral medicines help to keep people with COVID-19 from needing to be admitted to hospital and helps people to get better. All of the treatments in the PANORAMIC trial have been approved by the UK Medicines and Health Care Products Regulatory Agency (MHRA) for use in the study (which regulates the use of all medicines in the UK), and the study is approved by the Health Research Authority.
PURPOSE OF PANORAMIC
A lot of research has focussed on finding treatments for those already sick enough to be admitted to hospital.
PANORAMIC aims to find out if new antiviral treatments helps those with COVID-19 in the community prevents the need for being admitted to hospital and helps people recover quicker.
Exciting new antiviral treatments have been developed that have so far been tested in smaller studies in mostly unvaccinated people. We we do not yet know how effective these treatments will be in the general UK population which is largely vaccinated, so we need to do more studies to find this out.
Those consenting to be part of the study will be randomly selected to either be in a group who receives a course of an antiviral treatment, or a group that doesn’t. Two different groups are needed so the study team can see any difference in the health of those who received the antiviral treatment compared to those who didn’t.
A comparison is needed so that the study team can clearly see any difference between those who received the treatment compared to those who didn’t.
A comparison is needed so that the study team can clearly see any difference between those who received the treatment compared to those who didn’t.
This information will help the NHS to develop plans for how to best make new antiviral treatments available to patients who would benefit most from this treatment.
WHY SHOULD I SIGN UP?
No one is obliged to join the study and no one will receive a lesser standard of care by choosing not to join. All participants will be able to access any other NHS care that they would normally expect to receive
Those who do wish to join the study will be helping in the search for effective treatments for COVID-19 for use in the community. By joining as a participant you will be a critical part of this effort..
This national study aims to quickly generate information which will help the UK four nations to refine plans for making the antivirals available through normal routes to those who might benefit from them after the study has completed.
Your contribution will help us rapidly produce data about the effectiveness of these antivirals work in vaccinated people, whether you receive the antiviral treatment or not
